Navigation Links
Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
Date:5/28/2009

repair. GAM technology can also be applied to a number of other approaches benefiting from sustained localized release of therapeutic proteins and other agents. For more information about Cardium's Tissue Repair Company subsidiary, please visit www.t-r-co.com.

Cardium's Generx product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic designed for use by interventional cardiologists as a potential one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit www.cardiumthx.com or view its most recent annual report on Form 10-K and other reports as filed with the Securities and Exchange Commission and available on the company's website.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that the MATRIX study or other human clinical trials can be conducted and completed in an efficient and successful manner, that product formulation enhancements will be successful or will effectively simplify or expand the use of product candidates or technologies, that the GAM technology can be successfully broadened or applied to additional wound healing or tissue repair opportunities, that Excellarate or our other candidates will prove to be sufficiently safe and effective, that results or trends observed in one clinical study or procedu
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
2. Cardium Reports on Recent Highlights and Financial Results
3. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
4. Cardium Announces InnerCools Endovascular Cooling to be Featured on Science Channels Series Cool Stuff: How It Works
5. Cardium Completes $6.0 Million Financing
6. Cardium Announces Investor Presentation and Corporate Update Webcast
7. Cardium Reports on New York Citys Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients
8. Cardium Reports on Exchange Listing With NYSE Alternext US
9. Cardiums InnerCool Announces Launch of New Enhanced Website
10. Cardiums InnerCool Reports on Expanding Use of Therapeutic Hypothermia
11. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Alternext US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... The report, “Market Snapshot: Aesthetic Lasers ... Asia-Pacific” provides quantitative analysis of the three aesthetic ... body contouring devices, non-invasive body contouring devices and ... data by revenue and volume over the 2006 ... South Korea, Australia and India. It uses data ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water ... providing an 8 year warranty on its selected hot water ... up due to the impending winter season, it was important ... premium service that the company provides. As a result, Pro ... Wood and Bradford hot water tanks. , “Every installer ...
(Date:11/23/2014)... friends have more influence on teens, alcohol use than ... "We,ve known for a long time that ... use, but there are no common studies that distinguished ... influence on those decisions," Jonathon Beckmeyer, an assistant professor ... a university news release. Beckmeyer analyzed data gathered ...
(Date:11/23/2014)... a notable magnetic locks maker, has released a variety ... available at low rates up to 30% off. ... emergency doors. The emergency door adopts fireproof material and ... colors. All of the products are top-quality guaranteed. ... as easy as many people think. As a ...
(Date:11/23/2014)... November 23, 2014 To show thanks to ... new collection of white evening dresses for weddings. ... workers 24/7. , iFitDress.com is a distinguished dress manufacturer, and ... supported by worldwide customers for a very long time. The ... where a customer will be able to buy not only ...
Breaking Medicine News(10 mins):Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:Close Friends May Be Key to Teens' Drinking 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2
... Japan, May 30 Stronger health,systems, improved maternal and ... diseases are essential to African development,more than 40 heads ... highlighted in the action plan adopted at,the close of ... countries,were represented, along with many international organizations., Under ...
... sexual appetite. But stimulating new research in the Journal ... eye. A recent study shows that men who watched ... they were making decisions about money, soda, and candy. ... Luk Warlop (KULeuven, Belgium) found that the desire for ...
... study says , , FRIDAY, May 30 (HealthDay News) -- Repetitive ... the spine enough to result in a temporary loss of ... Previous research has suggested that gravity-related compression of the spine ... percent of their height in a normal day. Fortunately, this ...
... patients assume infertility is female issue, though almost half, infertility cases due ... ... factors, PURCHASE, N.Y., May 30 ... female condition, according,to an informal web survey conducted by IntegraMed, the leading ...
... 2008] Golf can be a good investment for the health, ... Karolinska Institutet. The death rate for golfers is 40 per ... age and socioeconomic status, which correspond to a 5 year ... the safest. , It is a well-known fact that ...
... 29, 2008) -- Physician-scientists from NewYork-Presbyterian Hospital/Columbia University ... at the American Society of Clinical Oncology Annual ... Among the most significant presentations are the following: ... Patients With Unresectable Metastatic Melanoma , Dr. Howard ...
Cached Medicine News:Health News:Stronger Health Systems and Better Maternal Health Critical to African Development, Japan Summit Affirms 2Health News:Stronger Health Systems and Better Maternal Health Critical to African Development, Japan Summit Affirms 3Health News:Football Can Shrink Players 2Health News:Fertility Specialists Decry Men's Reluctance to Seek Infertility Treatment 2Health News:Fertility Specialists Decry Men's Reluctance to Seek Infertility Treatment 3Health News:Golf prolongs life 2Health News:NYP/Columbia physician-scientists present at ASCO 44th annual meeting 2Health News:NYP/Columbia physician-scientists present at ASCO 44th annual meeting 3Health News:NYP/Columbia physician-scientists present at ASCO 44th annual meeting 4
(Date:11/24/2014)... SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2014 /PRNewswire/ ... James M. Gower is retiring from the board ... executive officer, and Raul Rodriguez , most recently serving ... the position of chief executive officer and join the board ... Board of Directors since 2005, will become chairman. Mr. Gower ...
(Date:11/24/2014)... , Nov. 24, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... Joseph Kim , President and CEO of Inovio Pharmaceuticals, will ... team to ring the Nasdaq Opening Bell tomorrow, Tuesday November ... September 15 th listing on the Nasdaq Global Select ... Dr. Kim said, "We are honored to ring the Nasdaq ...
(Date:11/22/2014)...  Sprout Pharmaceuticals today announced positive preliminary results from a ... flibanserin up to 200 mg at bedtime had no next-day ... 20 th Annual Fall Scientific Meeting of the Sexual ... Miami . The Phase 1 ... Letter and the Formal Dispute Resolution that was filed in ...
Breaking Medicine Technology:Rigel Announces Executive Management Changes 2Rigel Announces Executive Management Changes 3Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 3Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today ... 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) ... primary endpoint was the number of gout flares per ... ARCALYST at a weekly, self-administered, subcutaneous dose of either ...
... Feb. 28, 2011 Nile Therapeutics, Inc. (Nasdaq: ... development of novel therapeutics for cardiovascular disease, announced plans ... heart failure.  Nile plans to develop cenderitide (formerly CD-NP) ... decompensated heart failure (ADHF) patients continuously for up to ...
Cached Medicine Technology:ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 2ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 3ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 4ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 5ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 6ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 7ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 8ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 9ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 10Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure 2Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure 3Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure 4
The A350 test is used for POC testing in hospital emergency departments, replacing the need to draw blood for alcohol testing. Each hash mark is 0.02% or 20 mg/dL....
... Tests are available in 14 configurations including ... using Microgenics Antibody Technology, the SureStep™ MDMA ... care immunoassay targeted to detect MDMA that ... MDEA but no cross-reactivity to any isomer ...
... Drug Screen Tests are available in 14 ... (Ecstasy). Designed using Microgenics Antibody Technology, the ... point of care immunoassay targeted to detect ... MDA and MDEA but no cross-reactivity to ...
... SureStep™ Drug Screen Tests are available in ... MDMA (Ecstasy). Designed using Microgenics Antibody Technology, ... only point of care immunoassay targeted to ... both MDA and MDEA but no cross-reactivity ...
Medicine Products: